Actively Recruiting
Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors
Led by Shanghai Cell Therapy Group Co.,Ltd · Updated on 2025-08-28
12
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is a controlled, open-label exploratory clinical trial.
CONDITIONS
Official Title
Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 80 years old, weight 40kg or more; no gender limit
- Diagnosed with malignant solid tumors by histology or cytology and undergone radical surgery
- No lesions, local recurrence, or distant metastasis on imaging at study start; no brain metastasis
- For safety verification, positive immunohistochemical test for Survivin, P53, or MUC1
- ECOG performance status score of 0-1
- Adequate veins and no contraindications for blood cell collection surgery
- Good organ and bone marrow function including:
- Cardiac: Left ventricular ejection fraction at least 50%, normal electrocardiogram
- Platelets at least 90 x 10^9/L
- Hemoglobin at least 90 g/L without recent transfusion or erythropoietin dependence
- Total bilirubin no more than twice the upper normal limit
- Serum creatinine no more than 1.5 times the upper normal limit
- Transaminases (AST, ALT) no more than 2.5 times upper limit (5 times for liver cancer)
- INR or prothrombin time no more than 1.5 times upper limit
- Able to understand and willing to follow trial requirements
You will not qualify if you...
- Positive for HIV or syphilis antibodies
- Positive hepatitis B surface antigen and core or e antibody with viral DNA above detection limit or 1000 copies/ml
- Positive hepatitis C virus RNA above detection limit
- Any uncontrolled active infection, clotting disorder, or other major disease
- Pregnant or lactating women
- Active neuroautoimmune or inflammatory diseases (e.g., inflammatory bowel disease, lupus, ankylosing spondylitis, scleroderma, multiple sclerosis, Sjogren's syndrome) and receiving treatment
- Current use of immunosuppressants for organ transplant or long-term glucocorticoids not stopped at least 4 weeks before enrollment
- Severe allergies
- Central nervous system abnormalities such as seizures, strokes, dementia, cerebellar diseases, or autoimmune CNS diseases
- Major cardiovascular diseases with clinical significance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Mengchao Tumor Hospital
Shanghai, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here